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Surveillance of Viral Hepatitis – United States, 2015 
SUMMARY 
 
The Centers for Disease Control and Prevention’s (CDC) National Notifiable Diseases 
Surveillance System (NNDSS) (1) receives viral hepatitis case reports electronically each week 
from state and territorial health departments in the United States (U.S.) via CDC’s National 
Electronic Telecommunications System for Surveillance (NETSS), a computerized public health 
surveillance system. The surveillance system accepts case reports of acute and chronic infections 
from all states and the District of Columbia, though not all jurisdictions report their data. In 2015, 
a total of 48 states submitted reports of acute hepatitis B virus (HBV) infection, 40 submitted 
reports of acute hepatitis C virus (HCV) infection, 40 submitted reports of chronic HBV infection, 
and 40 submitted reports of chronic HCV infection. 
 
Viral hepatitis cases reported to NNDSS represent persons who were tested for and diagnosed with 
viral hepatitis infection based on specific surveillance case definitions 
(https://wwwn.cdc.gov/nndss/conditions/).  Most persons infected with viral hepatitis are 
asymptomatic and so are not identified or reported. In 2011, CDC developed a statistical method to 
account for cases that were neither diagnosed nor reported in estimating the actual number of new 
(acute) cases of hepatitis A virus (HAV), HBV, and HCV infections from the number of cases 
reported for each disease (2); estimates in this report were derived using this method. Since 
estimates before 2011 were obtained using a different, unpublished method, they cannot be 
compared with those since 2011. This Summary describes estimated trends during 2011-2015 and 
reported cases of acute HAV, HBV, and HCV infections in 2015. 
 
Hepatitis A: The number of reported cases of hepatitis A increased by 11.7% from 2011 to 2012 
(n=1,398 and 1,562, respectively), increased 14% to 1,781 cases in 2013, decreased 30.4% to 
1,239 cases in 2014, and increased 12.2% to 1,390 cases in 2015. The 2013 increase was partially 
due to a large 2013 hepatitis A outbreak among persons who consumed imported pomegranate 
seeds in several southwestern states and Hawaii (3). Although a few states (i.e., California, Florida, 
New York, Oregon, Texas, and Washington) reported increased cases in 2015, no hepatitis A 
outbreaks were reported.  Infant hepatitis A vaccination was first recommended for states west of 
the Mississippi in 1996, and universal infant vaccination was recommended in 2006. Since then, 
vaccination rates and evidence of vaccine-induced immunity in young persons have increased in 
the past decade (4, 5). Yet hepatitis A vaccination coverage levels remain lower than those for 
other routinely recommended vaccines (6). Additionally, many older adults remain unvaccinated 
and susceptible to infection. International travel is the most commonly reported risk for HAV 
infection (7). After adjusting for under-ascertainment and under-reporting (2), the estimated 
number of new HAV infections in 2015 was 2,800 (95% confidence interval [CI] =1,900–3,100). 
 
Hepatitis B:  The number of reported cases of acute hepatitis B decreased by 0.3% from 2011 to 
2012 (n=2,903 and 2,895 cases, respectively), increased 5.4% to 3,050 cases in 2013, decreased 
8.5% to 2,791 cases in 2014, and increased 20.7% to 3,370 cases in 2015. After adjusting for 
under-ascertainment and under-reporting (2), the estimated number of new HBV infections in 2015 
was 21,900 (95% CI= 12,500–53,600). 
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In addition to new cases of hepatitis B, chronic HBV infection remains a major public health 
challenge. CDC, using most recent national prevalence data, estimates that approximately 850,000 
persons are living with HBV in the U.S. (8, 9), although other studies have estimated this number 
to be as high as 2.2 million (10). Unpublished surveillance data from seven CDC-funded sites 
indicate about one-half of chronic HBV infections were among Asian/Pacific Islanders, and three 
quarters of chronic HBV infections were among persons born outside of the U.S. Other data reveal 
that 47%–70% of persons with HBV infection living in the U.S. were born in other countries 
where routine hepatitis B immunization was introduced more recently than in the U.S. Among 
persons born outside of the U.S. with chronic HBV infection, an estimated 58% migrated from 
Asia (10, 11). CDC mortality data show that disproportionate numbers of Asian/Pacific Islanders 
are dying with hepatitis B. CDC and the U.S. Preventive Services Task Force (USPSTF) 
recommend HBV testing for persons born in countries where HBV infection is endemic and for 
persons with sexual or bloodborne risks for infection because diagnosis of infection is the first step 
towards receipt of recommended care and treatment (12-14). 
Hepatitis C: Reported cases of acute HCV infection increased more than 2.9-fold from 
2010 through 2015, rising annually throughout this period. Examining annual trends beginning in 
2011, reported cases of acute HCV infection increased 44.3% from 2011 to 2012 (n=1,232 and 
1,778 cases, respectively), increased 20.3% to 2,138 cases in 2013, increased 2.6% to 2,194 cases 
in 2014, and increased 11% to 2,436 cases in 2015. The increase in acute HCV case reports 
reflects new infections associated with rising rates of injection-drug use, and, to a much lesser 
extent, improved case detection (15). Several early investigations of newly acquired HCV 
infections reveal that most occur among young, white persons who live in non-urban areas 
(particularly in states within the Appalachian, Midwestern, and New England regions of the 
country) (16); trends in these states likely indicate an overall increase in HCV incidence 
throughout the country (15, 17). States with the highest rate of new HCV infections (e.g., West 
Virginia, Kentucky, and Tennessee) did not receive CDC support for case finding during these 
reporting years (2011-2015). After adjusting for under-ascertainment and under-reporting (2), an 
estimated 33,900 (95% CI=26,800–115,000) new HCV infections occurred in 2015. 
Based on the data from national health surveys conducted in the 2003-2010 time period, 
approximately 3.5 million persons are currently infected with HCV (18).  Mortality among HCV-
infected persons—primarily adults aged 55–64 years—increased during 2006-2010 (19, 20). In 
2013, HCV associated deaths exceeded the combined number of deaths with 60 other infectious 
diseases as underlying causes (21). CDC data indicate the number of HCV-associated deaths 
increased 10.9% from 2011 through 2014 and decreased 0.2% to 19,629 in 2015. Approximately 
one-half of all deaths in 2015 occurred among persons aged 55-64 years. However, deaths 
associated with HCV are largely underestimated; the only large U.S. study of deaths among 
persons with confirmed HCV infection indicated that only 19% had HCV listed anywhere on the 
death certificate despite 75% having evidence of substantial liver disease (20). To increase the 
proportion of persons with HCV who are tested and linked to recommended care including 
curative treatment for HCV (12, 13), CDC and USPSTF recommend one-time testing for HCV 




Viral hepatitis is caused by infection with any of at least five distinct viruses: hepatitis A virus 
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E 
virus (HEV). Most viral hepatitis infections in the United States are attributable to HAV, HBV, 
and HCV. All three of these unrelated viruses can produce acute illness characterized by nausea, 
malaise, abdominal pain, and jaundice, although many of these acute infections are asymptomatic 
or cause only mild disease. Both HBV and HCV can also cause chronic disease that remains 
largely asymptomatic; thus, many persons infected with HBV or HCV are unaware they are 
infected and have clinically silent infections for decades until developing cirrhosis, end-stage liver 




Transmitted through the fecal-oral route, HAV is acquired in the United States primarily through 
close personal contact with an infected person and during foodborne outbreaks (21). Unlike 
hepatitis B and C, hepatitis A does not cause chronic infection. Since 1995, effective vaccines to 
prevent HAV infection have been available in the United States, increasing feasibility of 
eliminating indigenous transmission. In 1996, CDC’s Advisory Committee on Immunization 
Practices (ACIP) recommended administration of hepatitis A vaccine to persons at increased risk 
for the disease, including international travelers, men who have sex with men (MSM), persons 
who use drugs and persons who inject drugs (PWID), and children living in communities with 
high rates of disease (23). In 1999, ACIP expanded these recommendations to include children 
living in 11 states with average hepatitis A rates of >20 cases per 100,000 population and 
recommended that vaccination be considered for children in an additional six states with rates of 
10–20 cases per 100,000 population (24). In 2006, ACIP expanded these recommendations to 




HBV is transmitted by percutaneous or mucosal exposure to blood or body fluids of an infected 
person, such as from an infected mother to her newborn during childbirth, through close personal 
contact within households, through unscreened blood transfusion or unsafe injections in health- 
care settings, through injection drug use, and from sexual contact with an infected person. Adults 
with diabetes mellitus are at an increased risk for acquiring HBV infection if they share diabetes- 
care equipment such as blood glucose meters, finger stick devices, syringes and/or insulin pens. 
Hepatitis B vaccination is recommended for persons with diabetes s between 19-59 years of age 
(25). 
 
Risk for chronic HBV infection decreases with increasing age at onset of infection. Of infants 
who acquired HBV infection from their mothers at birth, as many as 90% become chronically 
infected compared with 30%–50% of children infected at age 1–5 years. This percentage is 
smaller among adults, for whom approximately 5% of all acute HBV infections progress to 
chronic infection (26, 27). 
 
Effective vaccines to prevent HBV infection have been available in the United States since 1981. 
Ten years later, a comprehensive strategy was recommended for the elimination of HBV 
transmission in the United States (28, 29); the strategy was revised to include catch-up 
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vaccination of older children, adolescents, and other populations. The current vaccine-based 
strategy for the elimination of HBV transmission encompasses the following four components: 
 
 Universal vaccination of infants beginning at birth;
 Prevention of perinatal HBV infection through routine screening of all pregnant women 
for HBV infection and provision of hepatitis B vaccine and immunoprophylaxis to infants 
born to hepatitis B surface antigen (HBsAg)-positive mothers;
 Routine vaccination of previously unvaccinated children and adolescents; and
 Vaccination of adults at increased risk for infection (including health-care workers, 
dialysis patients, adults with diabetes, household contacts and sex partners of persons 
with chronic HBV infection, recipients of certain blood products, persons with a recent 
history of having multiple sex partners concurrently, those infected with a sexually 
transmitted disease, MSM, and PWID).
 
In addition to hepatitis B vaccination, efforts have been made to improve care and treatment for 
the estimated 850,000 persons living with hepatitis B in the United States. This number is likely 
substantially higher: an analysis based on census data and surveys conducted in the country of 
origin for persons migrating to the United States estimate that as many as 2.2 million persons are 
living with HBV infection. Many HBV-infected persons are unaware of their infection status 
(11). Because testing is the first critical step towards receipt of recommended care and treatment 
(10), in 2008 CDC and USPSTF recommended HBV testing for persons born in countries where 
HBV infection is endemic and for other persons at risk. These guidelines stress the need for 
testing persons at high risk for infection, conducting contact management, educating patients, and 
administering FDA- approved therapies for treating hepatitis B. Other recent guidelines address 
the appropriate management of chronic HBV infection among surgeons, other health-care 




HCV is transmitted primarily through percutaneous (parenteral) exposure that can result from 
injection-drug use, needle stick injuries, and inadequate infection control in health-care settings. 
Much less often, HCV transmission occurs among HIV-positive persons, especially MSM, as a 
result of sexual contact with an HCV-infected partner (31, 32), among persons who receive 
tattoos in unregulated settings (32), and among infants born to HCV-infected mothers (33). After 
adjustment for populations not sampled in the 2003-2010 National Health and Nutrition 
Examination Survey (NHANES) household surveys (e.g., incarcerated and homeless 
populations), an estimated 3.5 million persons are living with HCV infection in the United States 
(15). 
 
Approximately 75%–85% of newly infected adults and adolescents develop chronic HCV infection 
(34). A single positive anti-HCV result cannot distinguish between acute and chronic HCV 
infection or between current or resolved (cleared) HCV infection. To detect current infection, the 
revised CDC algorithm for HCV testing includes anti-HCV testing and if positive, a nucleic acid 
test (NAT) (35). For reporting purposes, health departments must make the distinction between 
acute and chronic HCV infection based on both 1) laboratory testing to detect whether anti-HCV is 
positive or negative; and 2) clinical criteria from providers regarding the presence of signs and 
symptoms indicative of liver disease or acute HCV infection. Repeat laboratory tests may be used 
to determine serologic conversion from anti-HCV negative to anti-HCV positive.  The 2012 case 
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definition for “past or present” HCV infection requires that a case meet one or more of the 
following laboratory criteria: anti-HCV positive (repeatedly reactive) by enzyme-linked 
immunosorbent assay EIA, verified by at least one more specific assay, or HCV Recombinant 
Immunoblot Assay RIBA positive, or HCV NAT positive, or anti-HCV screening-test positive 
with an assay-specific signal-to-cutoff ratio predictive of a true case. The assessment process used 
to classify cases as acute or chronic requires, on average, review of at least four records by 
hepatitis surveillance staff in health departments (36). No clinical symptoms are required; 
however, the case must be known to not be acute.  
National recommendations for preventing HCV infection (37) include screening and testing 
donors of blood, other tissues and organs, inactivating HCV in plasma-derived products, testing 
persons at risk for HCV infection, providing risk-reduction counseling and recommended care 
and treatment, increasing access to safe injection equipment for PWID, and consistently 
implementing and practicing infection control in health-care settings. In 2010, FDA approved 
point-of-care tests for HCV infection that yield prompt results available to patients during the 
same clinical visit (38). In 2012, CDC augmented existing recommendations for HCV screening 
based on risk to include recommendations for one-time screening for HCV infection among all 
persons born during 1945–1965 (39); persons born during these years have an estimated 3% 
prevalence of HCV antibodies, which is six times higher than the prevalence seen in adults born 
in other years (39). Of all persons living with HCV infection, about 75% were born during 1945–
1965; a similar percentage of HCV-associated deaths can be attributed to this birth cohort (40). 
The goal of birth-cohort HCV testing is to identify unrecognized infections among the segment of 
the population at highest risk for HCV-associated morbidity and mortality, thereby increasing 
opportunities for persons infected with HCV to benefit from appropriate care and treatment. 
Linkage to care and treatment is critical to improving health outcomes for persons found to be 
infected with HCV. Such linkage is particularly important in light of major advancements that 
have been made in HCV treatments. For patients infected with HCV, treatment previously 
consisted of pegylated interferon (PEG-INF) combined with oral doses of ribavirin (41). 
Approximately 40%--50% of HCV-infected patients receiving this therapy cleared their infection 
(41). However, HCV treatment improved drastically in 2011 with development of the initial 
direct-acting oral agents telaprevir and boceprevir, which were capable of achieving a sustained 
virologic response (SVR) rate of >80% (41, 42). In the United States, these two drugs were 
replaced with all-oral direct-acting antiviral agents (DAAs), simeprevir and sofosbuvir, which 
were approved by FDA in 2013 (43). When given in combination with PEG-INF and ribavirin or 
as an all-oral combination regimen for a duration of 8-12 weeks, these agents increase SVR rates 
to >90% (44, 45). In 2014, two all-oral regimens, Harvoni (ledipasvir/sofosbuvir) and Viekira 
Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), were licensed for the 
treatment of HCV. Daklinza (daclatasvir), was approved in July 2015 for use with sofosbuvir as 
the first 12-week, all-oral treatment option for patients with chronic hepatitis C virus genotype 3. 
Also approved in July 2015 was Technivie (ombitasvir, paritaprevir and ritonavir), used in 
combination with ribavirin for the treatment of HCV genotype 4 infections in patients that do not 
have scarring or poor liver function (cirrhosis). Newer, all oral agents are being continually added 
and have become the standard of care in the United States. In 2016, Zepatier 
(elbasvir/grazoprevir) and Epclusa (sofosbuvir/velpatasvir) (46) were FDA approved, the latter 
drug for all HCV genotypes. Evidence-based guidance is available from the American 
Association for the Study of Liver Diseases (AASLD)/ Infectious Disease Society of America 
(IDSA) to assist providers caring for HCV-infected patients (47). The AASLD/IDSA HCV 
guidance is continuously updated to incorporate new information regarding HCV testing, linkage 
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to care, and treatment (http://www.hcvguidelines.org). 
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Sources of Information 
CDC relies on several sources of information to determine the incidence, prevalence, trends, and 
burden of viral hepatitis A, B, and C disease. 
 
National Notifiable Diseases Surveillance System (NNDSS) 
 
The basis for most case reports is passive surveillance through the National Notifiable 
Diseases Surveillance System (NNDSS). State, local, and territorial health departments 
report acute (incident) cases of hepatitis A, hepatitis B, and hepatitis C through this system 
on a weekly basis. Some but not all states also report cases of chronic hepatitis B cases and 
past or present infections of hepatitis C through NNDSS. Since 1990, states have been 
electronically submitting individual case reports (absent of personal identifiers) to CDC. 
States’ participation in notifying CDC of cases of nationally notifiable diseases, including 
viral hepatitis, is voluntary. Collecting, verifying, and reporting the many cases of hepatitis B 
and C in the United States (estimated at more than 4 million) are beyond the capability of 
many health departments. Reports of chronic hepatitis B and C are included in this 
Surveillance Summary only from those states granting CDC permission to publish those 
counts. 
 
National surveillance for viral hepatitis (including acute hepatitis A, hepatitis B, and hepatitis C; 
chronic hepatitis B; and past or present hepatitis C) is based on case definitions developed and 
approved by the Council of State and Territorial Epidemiologists (CSTE) and CDC. Reported 
cases of acute and chronic viral hepatitis are required to meet specific clinical and laboratory 
criteria (available at: https://wwwn.cdc.gov/nndss/conditions/notifiable/2014/. 
However, these criteria are evaluated at state or local health departments and are not validated by 
CDC. Although states may classify cases as confirmed, probable, and suspect, only confirmed 
cases of acute viral hepatitis are presented in this report. Updated CSTE Case definitions are 
available at the CSTE website: https://wwwn.cdc.gov/nndss/case-definitions.html. 
Adjustments to Reported Cases from the National Notifiable Diseases Surveillance System 
 
To better estimate the incidence of acute hepatitis A, hepatitis B, and hepatitis C in the United 
States, CDC developed a model to account for under-ascertainment and under-reporting of cases 
of viral hepatitis. The model factored in the probabilities of an infected person developing 
symptoms such as jaundice, referral to care and treatment, and rates of reporting to local and 
state health departments. Results of the analysis estimated that reported cases represent 1 of 
every 2 hepatitis A cases, 1 of every 6.5 acute hepatitis B cases, and 1 of every 13.9 acute 
hepatitis C cases (2). To obtain the estimated number of cases of acute HAV, HBV, and HCV 
infections after accounting for under-ascertainment and under-reporting, these new estimators 
were applied to the acute hepatitis case data from NNDSS beginning in 2011. Incidence data 
reported in Surveillance Summaries from 2011 onward, including this report, reflect these 
estimators. Because earlier estimates were based on different (and unpublished) calculations, 
current estimates cannot be used to deduce trends by comparison with estimations obtained in 
years prior to 2011; still, trends in reported cases can be evaluated (e.g., the trend in the increase 
in acute hepatitis C first observed in 2011 among nationally reported cases). 
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Enhanced Viral Hepatitis Surveillance Sites 
Background 
 
In November 2012, CDC funded seven health departments to conduct enhanced viral hepatitis 
surveillance. Each quarter, a dataset of cumulative cases from each site is sent to CDC through the 




The seven funded sites (the states of Florida, Massachusetts, Michigan, New York, and 
Washington and cities of Philadelphia and San Francisco) represent a combined population of 
approximately 57.8 million persons. In each of these jurisdictions, clinical laboratories are 
mandated to submit laboratory reports from persons with positive HBV and HCV test results to 
state or local health departments. Participating health departments routinely review each report to 
assess whether current case definitions are met as established by CSTE and CDC. Sites are also 
required to de-duplicate all chronic cases of viral hepatitis. To determine whether a case is new, 
each site matches new case reports to existing cases in the surveillance registry using personal 
identifying information. New cases are added to an electronic registry, whereas duplicate cases 
are used to update previous reports. Most health departments collect basic demographic data (e.g., 
age and sex) from the laboratory reports. Efforts vary by site regarding the level of investigation 
undertaken to collect and store supplemental information (e.g., risk factor data) from patients or 
their providers. Health departments in all funded sites conduct follow-up for a sample of cases 
(and all cases in some sites such as New York State) to obtain clinical, laboratory, and 
epidemiologic information, including risk exposures and behaviors. 
 
Data analyses from participating enhanced surveillance sites presented in this surveillance report 
were conducted on all serologically confirmed cases of chronic hepatitis B and chronic (past or 
present) hepatitis C infection reported for the year 2015. Rates were calculated using appropriate 




The number of cases of chronic HBV infection and past or present HCV infection from 
participating enhanced surveillance sites included in this report is likely an underestimate of the 
true burden of disease, because cases of chronic infection are generally asymptomatic and less 
likely to be identified and reported. Additionally, data from these sites are not representative of the 
U.S. population; because not all sites conduct comprehensive follow-up, data regarding 









Death certificates are completed for all deaths registered in the United States. Information from 
death certificates is provided by funeral directors, attending physicians, medical examiners, and 
coroners; certificates are filed in vital statistics offices within each state and the District of 
Columbia. Through a program called the National Vital Statistics System (NVSS) (48), 
information from death certificates is compiled by CDC’s National Center for Health Statistics 
(NCHS) to produce national multiple-cause-of-death (MCOD) data (48); causes of death are 
coded in accordance with the International Classification of Diseases, Tenth Revision (ICD-10) 
(49). MCOD data are used to determine the national burden of mortality associated with viral 
hepatitis and to characterize decedents. 
 
A major study of death certificates from 1999–2007 revealed that in 2007, the annual number of 
deaths associated with HCV infection exceeded the annual number of deaths associated with HIV 
infection (18). A more recent study using death certificate data from 2003--2013 showed that the 
number of deaths associated with HCV infection continued to increase and in 2012 surpassed the 
combined number of deaths associated with 60 other nationally notifiable infectious conditions that 
are routinely reported to CDC (50).   
 
Methods 
We obtained and analyzed 2011–2015 national multiple-cause mortality data through NVSS. The 
following case definitions were used to identify a death associated with hepatitis A, B, and C. 
 
Any death record with a report of any of the following ICD-10 codes listed as the underlying or 
one of the multiple (e.g., contributing) causes of death in the record axis: 
 
 Hepatitis A (ICD-10: B15), 
 Hepatitis B (ICD-10: B16, B17.0, B18.0, and B18.1), or 
 Hepatitis C (ICD-10: B17.1 and B18.2). 
 
Demographic information on age, race/ethnicity, and sex were examined. Deaths were divided 
into six age categories: 0–34, 35–44, 45–54, 55–64, 65–74, and >75 years. Race was divided into 
the following categories: white, non-Hispanic; black, non-Hispanic; Hispanic; Asian/Pacific 
Islander (API); and American Indian/Alaska Native (AI/AN). To calculate national mortality 
rates, the number of deaths associated with each type of hepatitis was divided by the total U.S. 
Census population for each demographic characteristic. Rates on race/ethnicity, sex, and overall 




The following limitations to the mortality data should be taken into account when interpreting 
these data. 
 
 Differences in recording practices of death certificate information may cause 
misclassification of ICD-10 codes and demographic information. 
 Certain racial/ethnic populations likely are underrepresented in U.S. Census data (the 
Surveillance for Viral Hepatitis — United States, 2015 
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denominator for calculating rates), potentially causing overestimated rates for these 
populations. 
 HBV and HCV infections are often underreported as causes of death on death certificates.
These analyses do not adjust for deaths resulting from undiagnosed viral hepatitis
infections.
 Death records listing more than one type of viral hepatitis infection were counted once for
each type of infection. For example, a death with ICD-10 codes for both hepatitis B and C
virus infections is counted once as a hepatitis B death and once as a hepatitis C death.
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INVESTIGATION OF HEALTHCARE-ASSOCIATED 
OUTBREAK CASES  
In 2015, CDC participated in 12 state-based investigations of healthcare-associated outbreaks of 
HCV infection with two or more confirmed outbreak-related cases. Additional information may 
be found at the following link that summarizes known outbreaks that occurred during 2008–2015 
(http://www.cdc.gov/hepatitis/statistics/healthcareoutbreaktable.htm). 
Table 1.1. Hepatitis C Outbreaks by Setting ― United States, 2015 








Known or suspected mode of 
transmission
Outpatient 
Prolotherapy clinic California >1,500 5 
Syringe reuse contaminating 
medication vials used for >1 
patient and use of single-dose 
vials for >1 patient 
Insulin infusion 
clinic  
California 92 9 
Unsafe practices related to 
assisted blood glucose monitoring 
including use of finger stick 
devices for >1 person and 
inadequate cleaning and 




Michigan 122 2 
Syringe reuse contaminating 
medication vials used for >1 
patient 
Cardiology clinic West Virginia >2,000 5 
Use of single-dose vials for >1 
patient 
Hospital 
Hospital Utah 7,217 >7
Drug diversion by nurse (* 
Investigation ongoing) 
Surveillance for Viral Hepatitis — United States, 2015 
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Table 1.1 (cont’d). Hepatitis C Outbreaks by Setting ― United States, 2015 














New Jersey 237 2 
Multiple lapses in infection 
control identified, including hand 
hygiene and glove use, vascular 
access care, medication 





New Jersey 84 2 
Multiple lapses in infection 
control identified, vascular access 
care, medication preparation, 




New Jersey 98 2 
Multiple lapses in infection 
control identified, including hand 
hygiene and glove use, vascular 
access care, medication 





Pennsylvania 115 3 
Multiple lapses in infection 
control identified, medication 





Pennsylvania 130 3 
Multiple lapses in infection 
control identified, medication 





Pennsylvania 97 2 
Multiple lapses in infection 
control identified, medication 
preparation close to treatment 
area, Use of single-dose vials for 
>1 patient, no separation of dirty




California 28 3 
Breaches in environmental 
cleaning and disinfection 
practices 
Additional information may be found at the following link that summarizes known outbreaks that occurred 
during 2008–2015: http://www.cdc.gov/hepatitis/statistics/healthcareoutbreaktable.htm. 
15 
 HEPATITIS A 
Hepatitis A 
In 2015, a total of 1,390 cases of hepatitis A were reported to CDC from 50 states (Table 2.1). 
The overall incidence rate in 2015 was 0.4 cases per 100,000 population. Actual acute cases are 
estimated to be 1.96 times the number of reported cases in any year. After adjusting for under-
ascertainment and under-reporting, an estimated 2,800 hepatitis A cases (95% CI=1,900--3,100) 
occurred in 2015. (Data for 2015 were unavailable for the District of Columbia.) 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Acute hepatitis is defined as acute illness with 1) discrete onset of symptoms (e.g., fever, 
headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain) and 2) jaundice, 
elevated serum alanine aminotransferase (ALT), or aspartate aminotransferase (AST) levels. 
Laboratory Criteria 
Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive.
Surveillance for Viral Hepatitis — United States, 2015 
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Table 2.1. Reported cases of hepatitis A, nationally and by state or jurisdiction ― United 
States, 2011–2015 
State 
2011 2012 2013 2014 2015 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
Alabama 8 0.2 19 0.4 10 0.2 15 0.3 23 0.5 
Alaska 4 0.6 1 0.1 1 0.1 1 0.1 4 0.5 
Arizona 77 1.2 93 1.4 66 1.0 29 0.4 54 0.8 
Arkansas 3 0.1 8 0.3 9 0.3 2 0.1 10 0.3 
California 186 0.5 209 0.5 255 0.7 142 0.4 179 0.5 
Colorado 21 0.4 28 0.5 51 1.0 23 0.4 25 0.5 
Connecticut 18 0.5 23 0.6 19 0.5 23 0.6 9 0.3 
Delaware 2 0.2 9 1.0 4 0.4 1 0.1 2 0.2 
District of 
Columbia 
U U U U U U U U U U 
Florida 87 0.5 87 0.5 115 0.6 90 0.5 108 0.5 
Georgia 27 0.3 46 0.5 36 0.4 24 0.2 30 0.3 
Hawaii 8 0.6 5 0.4 16 1.1 5 0.4 6 0.4 
Idaho 6 0.4 11 0.7 8 0.5 7 0.4 9 0.5 
Illinois 73 0.6 67 0.5 79 0.6 82 0.6 57 0.4 
Indiana 24 0.4 11 0.2 32 0.5 20 0.3 19 0.3 
Iowa 8 0.3 7 0.2 17 0.6 12 0.4 16 0.5 
Kansas 4 0.1 15 0.5 11 0.4 7 0.2 7 0.2 
Kentucky 10 0.2 25 0.6 24 0.5 19 0.4 16 0.4 
Louisiana 5 0.1 7 0.2 14 0.3 5 0.1 5 0.1 
Maine 6 0.5 9 0.7 10 0.8 8 0.6 8 0.6 
Maryland 26 0.4 28 0.5 29 0.5 27 0.5 19 0.3 
Massachusetts 39 0.6 40 0.6 43 0.6 43 0.6 34 0.5 
Michigan 70 0.7 100 1.0 83 0.8 45 0.5 51 0.5 
Minnesota 27 0.5 29 0.5 32 0.6 19 0.3 21 0.4 
Mississippi 7 0.2 11 0.4 5 0.2 3 0.1 2 0.1 
Missouri 13 0.2 20 0.3 8 0.1 20 0.3 9 0.1 
Montana 3 0.3 6 0.6 6 0.6 5 0.5 2 0.2 
Nebraska 5 0.3 16 0.9 13 0.7 9 0.5 6 0.3 
Nevada 5 0.2 10 0.4 19 0.7 5 0.2 11 0.4 
New 
Hampshire 
0 0.0 6 0.5 9 0.7 5 0.4 2 0.2 
New Jersey 79 0.9 60 0.7 68 0.8 59 0.7 59 0.7 
New Mexico 7 0.3 10 0.5 20 1.0 8 0.4 6 0.3 
New York 113 0.6 111 0.6 167 0.8 84 0.4 123 0.6 
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Table 2.1 (cont’d). Reported cases of hepatitis A, nationally and by state or jurisdiction ― 
United States, 2011–2015 
State 
2011 2012 2013 2014 2015 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
North 
Carolina 
31 0.3 34 0.3 46 0.5 38 0.4 45 0.4 
North 
Dakota 
0 0.0 2 0.3 9 1.2 9 1.2 5 0.7 
Ohio 39 0.3 36 0.3 59 0.5 32 0.3 36 0.3 
Oklahoma 11 0.3 12 0.3 14 0.4 17 0.4 11 0.3 
Oregon 11 0.3 9 0.2 29 0.7 13 0.3 28 0.7 
Pennsylvania 60 0.5 62 0.5 53 0.4 48 0.4 43 0.3 
Rhode 
Island 
8 0.8 3 0.3 4 0.4 8 0.8 4 0.4 
South 
Carolina 
11 0.2 6 0.1 14 0.3 6 0.1 16 0.3 
South 
Dakota 
2 0.2 0 0.0 4 0.5 3 0.4 2 0.2 
Tennessee 23 0.4 23 0.4 20 0.3 12 0.2 14 0.2 
Texas 138 0.5 134 0.5 109 0.4 124 0.5 147 0.5 
Utah 8 0.3 4 0.1 12 0.4 8 0.3 8 0.3 
Vermont 6 1.0 2 0.3 7 1.1 1 0.2 3 0.5 
Virginia 30 0.4 49 0.6 36 0.4 27 0.3 50 0.6 
Washington 31 0.5 29 0.4 45 0.6 26 0.4 26 0.4 
West 
Virginia 
8 0.4 8 0.4 4 0.2 12 0.6 8 0.4 
Wisconsin 8 0.1 21 0.4 37 0.6 7 0.1 9 0.2 
Wyoming 2 0.4 1 0.2 0 0.0 1 0.2 3 0.5 
U.S. 1398 0.4 1562 0.5 1781 0.6 1239 0.4 1390 0.4 
Source: CDC, National Notifiable Diseases Surveillance System. 
*Rate per 100,000 population.
U=No data available for reporting.
 The number of hepatitis A cases reported in the United States increased 11.7% from
2011 through 2012 (1,398 cases to 1,562 cases), increased 14.0% from 2012 through
2013, and declined 30.4% from 2013 through 2014. Compared with data for 2014,
cases of acute hepatitis A increased 12.2% to 1,390 cases in 2015.
 The national rate of hepatitis A remained the same from 2014 through 2015 at 0.4
cases/100,000 population.
 By state, in 2015, rates of hepatitis A ranged from 0.1 cases per 100,000 in Louisiana,
Mississippi, and Missouri to 0.8 cases per 100,000 population in Arizona.
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Map 2.1.  2015 State Hepatitis A Incidence Compared to Healthy People 2020 National Goal*
• Of the 50 reporting states, 22 (44%) met the Healthy People 2020 goal
(https://www.healthypeople.gov/) of reducing hepatitis A incidence to
≤0.3 cases/100,000 population: Arkansas, Connecticut, Delaware,
Georgia, Indiana,  Kansas, Louisiana, Maryland, Mississippi, Missouri,
Montana, Nebraska, New Hampshire, New Mexico, Ohio, Oklahoma,
Pennsylvania, South Carolina, South Dakota, Tennessee, Utah, and
Wisconsin.
• The incidence of hepatitis A was above the Healthy People 2020 goal
for 28 states:  Alabama, Alaska, Arizona, California, Colorado, Florida,
Hawaii, Idaho, Illinois, Iowa, Kentucky, Maine, Massachusetts,
Michigan, Minnesota, Nevada, New Jersey, New York, North Carolina,
North Dakota, Oregon, Rhode Island, Texas, Vermont, Virginia,
Washington, West Virginia, and Wyoming.
• Of the 28 states with rates above the Healthy People 2020 goal, four
states (Arizona, New Jersey, North Dakota, and Oregon) had rates more
than twice the national goal.
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Table 2.2. Select clinical characteristics of hepatitis A cases* reported in the United States, 2015
Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 1,390 hepatitis A cases were reported during 2015.
†Case reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with
any other response were excluded.
§Numbers and percentages represent only those case reports for which data regarding clinical characteristics were
available; numbers likely are underestimates.
• Of the 1,390 case reports of acute hepatitis A received during 2015,
62.2% included information about whether the patient had jaundice,
62.6% included information regarding hospitalization caused by hepatitis
A, and 57.6% included information on deaths from hepatitis A.
• Jaundice was reported for 541 (62.5%) of the 865 hepatitis A case reports
that included information about jaundice.
• Hospitalization as the result of hepatitis A was reported for 411 (47.2%)
of the 870 hepatitis A case reports that included information about
hospitalization.
• Death as the result of hepatitis A was reported for 8 (1.0%) of the 801
hepatitis A case reports that included information about death.
Clinical characteristic 
Availability of valid data† for 
clinical characteristic 
Cases with clinical 
characteristic§  
No. % No. % 
Jaundice 865 62.2 541 62.5 
Hospitalized for hepatitis A 870 62.6 411 47.2 
Died from hepatitis A 801 57.6 8 1.0 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 The number of reported hepatitis A cases declined 88.3%, from 13,397 in 2000 to 1,562 in 2012;
increased 14% (to 1,781 cases) from 2012 through 2013; declined 30.4% (to 1,239 cases) from 2013
through 2014; and increased 12.2% (to 1,390 cases) from 2014 through 2015.
Surveillance for Viral Hepatitis — United States, 2015 
21







































Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2000 through 2015, rates of reported hepatitis A declined, except for a slight increase in 2012 and
2013 among all age groups except those aged 0–9 and 10–19 years.
 When comparing the 2015 hepatitis A rates of all age groups, persons aged 20–29 years had the highest
rate (0.6 cases per 100,000 population); persons aged 0–9 years had the lowest rate (0.1 cases per
100,000 population).
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Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2000 through 2011, reported rates of hepatitis A among males and females declined, and by 2011,
rates in these two groups were similar.
 In 2015, the incidence rate was 0.5 cases per 100,000 population for males and 0.4 cases per 100,000
population for females.
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Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2000 through 2007, the incidence rate of hepatitis A among Hispanics was higher than that among
other racial/ethnic populations.
 Since 2008, the incidence rate of hepatitis A has been higher for Asians/Pacific Islanders (0.6 cases per
100,000 population in 2015) than for other racial/ethnic populations.
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Figure 2.5. Availability of information on risk exposures/behaviors associated with hepatitis A 










Source: CDC, National Notifiable Diseases Surveillance System. 
*Includes case reports indicating the presence of at least one of the following risks 2–6 weeks prior to onset of acute,
symptomatic hepatitis A: 1) having traveled to hepatitis A-endemic regions of Mexico, South/Central America, Africa,
Asia/South Pacific, or the Middle East; 2) having sexual/household or other contact with suspected/confirmed hepatitis
A patient; 3) being a child/employee in day-care center/nursery/preschool or having had contact with such persons; 4)
being involved in a foodborne/waterborne outbreak; 5) being a man who has sex with men; and 6) using injection drugs.
 Of the 1,390 case reports of hepatitis A received by CDC during 2015, a total of 517 (37%) did not
include a response (i.e., a “yes” or “no” response to any of the questions about risk exposures and
behaviors) to enable assessment of risk exposures or behaviors.
 Of the 873 case reports that contained risk exposure/behavior information:
o 752 (86.1%) indicated no risk exposures/behaviors for acute hepatitis A and
o 121 (13.9%) indicated at least one risk exposure/behavior for acute hepatitis A
during the 2–6 weeks prior to onset of illness.
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sex with men¶




Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 1,390 case reports of hepatitis A were received in 2015.
†More than one risk exposure/behavior may be indicated on each case report.
§No risk data reported.
¶A total of 726 hepatitis A cases were reported among males in 2015. Source: CDC.
Figure 2.6a presents reported risk exposures/behaviors for acute hepatitis A during the incubation period, 
2–6 weeks prior to onset of symptoms: 
 Of the 578 case reports that included information about travel, 7.6% (n= 44) indicated travel outside of
the United States or Canada.
 Of the 520 case reports that included information about injection-drug use, 3.5% (n=18) indicated use of
injection drugs.
 Of the 100 case reports from males that included information about sexual preference/practices, 8.0%
(n=8) indicated having sex with another man.
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Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 1,390 case reports with hepatitis A were received in 2015.
†More than one risk exposure/behavior may be indicated on each case report.
§No risk data reported.
Figure 2.6b presents reported risk exposures/behaviors for acute hepatitis A during the incubation period, 
2–6 weeks prior to onset of symptoms: 
 Of the 563 case reports that contained information about sexual/household contact with a hepatitis A-
infected person, 2.1% (n=12) indicated such contact.
 Of the 738 case reports that included information about employment or attendance at a nursery, day-care
center, or preschool, 1.9% (n=14) indicated working at or attending one of these facilities.
 Of the 650 case reports that included information about household contact with an employee of or a
child attending a nursery, day-care center, or preschool, 3.5% (n=23) indicated such contact.
 Of the 598 case reports that included information about linkage to an outbreak, 1.5% (n=9) indicated
exposure that may have been linked to a common-source foodborne or waterborne outbreak.
 Of the 563 case reports that included information about additional contact (i.e., other than household or
sexual contact) with a person confirmed or suspected of having hepatitis A, 0.4% (n=2) indicated such
contact.
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Table 2.3. Number and rate* of hepatitis A-related deaths†, by demographic characteristics 
and year — United States, 2011–2015 
Demographic characteristic 
2011 2012§ 2013 2014 2015 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years) 
0–34 0 0.00 2 0.00 2 0.00 0 0.00 1 0.00 
35–44 1 0.00 5 0.01 2 0.00 4 0.01 4 0.01 
45–54 11 0.02 12 0.03 13 0.03 7 0.02 6 0.01 
55–64 16 0.04 23 0.06 30 0.08 28 0.07 19 0.05 
65–74 12 0.05 17 0.07 19 0.08 19 0.07 16 0.06 




44 0.02 51 0.02 63 0.02 51 0.02 45 0.02 
Black, NH 10 0.03 8 0.02 6 0.01 11 0.03 7 0.02 
Hispanic 6 0.02 8 0.02 8 0.02 10 0.02 10 0.03 
Asian/Pacific 
Islander 




1 0.04 2 0.08 0 0.00 2 0.10 1 0.04 
Sex 
Male 37 0.02 46 0.03 50 0.03 42 0.02 38 0.02 
Female 32 0.02 31 0.02 30 0.01 34 0.02 29 0.02 
Overall 69 0.02 77 0.02 80 0.02 76 0.02 67 0.02 
Source: CDC, National Vital Statistics System. 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on
the International Classification of Diseases, 10th Revision (ICD-10) codes B15 (hepatitis A).
§One death in 2012 is not represented under the race/ethnicity category due to missing data.
 In 2015, the overall hepatitis A-related mortality rate was 0.02 deaths per 100,000
population (n=67).
 From 2011–2015, the hepatitis A-related mortality rate remained steady at 0.02
deaths/100,000 population each year.
 In 2015, age-specific mortality rates for hepatitis A increased with advancing age:
no deaths/100,000 population among persons aged 0–34 years, 0.01 deaths/100,000
population among persons aged 35–54 years, 0.05 deaths/100,000 population among
persons 55–64 years, 0.06 deaths/100,000 population among persons 65–74 years, and
0.10 deaths/100,000 population among persons aged ≥75 years.
 In 2015, American Indians/Alaska Natives had the highest hepatitis A-related mortality
rate at 0.04 deaths/100,000 population.
 In 2015, hepatitis A-related mortality rates were the same for both females and males
(0.02 deaths/100,000 population). From 2011–2015, the hepatitis A-related mortality
rate remained relatively stable for males and females.
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HEPATITIS B 
Acute Hepatitis B 
In 2015, a total of 3,370 cases of acute hepatitis B were reported to CDC from 48 states (Table 
3.1); the actual number of acute cases is estimated to be 6.48 times the number of reported 
cases in any year. The overall incidence rate for 2015 was 1.1 cases per 100,000 population. 
After adjusting for under-ascertainment and under-reporting, an estimated 21,900 acute 
hepatitis B cases (95% CI=12,500–53,600) occurred in 2015. (Data for 2015 were unavailable 
for the District of Columbia, Rhode Island, and Wyoming.) 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Acute hepatitis is defined as acute illness with 1) discrete onset of symptoms* (e.g., fever, 
headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain) and 2) jaundice or 
elevated serum alanine aminotransferase (ALT) >100 IU/L. 
Laboratory Criteria 
 Hepatitis B surface antigen (HBsAg) positive
AND 
 Immunoglobulin M (IgM) antibody to hepatitis B core antigen (IgM anti-HBc) positive
(if done).
*A documented negative HBsAg laboratory test result within 6 months prior to a positive test
result (either by HBsAg, hepatitis B "e" antigen [HBeAg], or hepatitis B virus nucleic acid
testing [HBV NAT] including genotype) does not require an acute clinical presentation to meet
the surveillance case definition.
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Table 3.1. Reported cases of acute hepatitis B, nationally and by state or jurisdiction ― 
United States, 2011–2015 
State 
2011 2012 2013 2014 2015 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
Alabama 119 2.5 79 1.6 90 1.9 117 2.4 101 2.1 
Alaska 3 0.4 1 0.1 1 0.1 3 0.4 3 0.4 
Arizona 14 0.2 14 0.2 28 0.4 31 0.5 25 0.4 
Arkansas 57 1.9 74 2.5 50 1.7 28 0.9 36 1.2 
California 157 0.4 136 0.4 138 0.4 110 0.3 160 0.4 
Colorado 23 0.4 24 0.5 24 0.5 29 0.5 28 0.5 
Connecticut 19 0.5 15 0.4 8 0.2 9 0.3 6 0.2 
Delaware 13 1.4 11 1.2 14 1.5 8 0.9 8 0.8 
District of 
Columbia 
U U U U U U U U U U 
Florida 213 1.1 247 1.3 323 1.7 313 1.6 432 2.1 
Georgia 142 1.4 109 1.1 104 1.0 103 1.0 119 1.2 
Hawaii 6 0.4 5 0.4 4 0.3 6 0.4 14 1.0 
Idaho 2 0.1 5 0.3 13 0.8 6 0.4 8 0.5 
Illinois 85 0.7 86 0.7 94 0.7 58 0.5 55 0.4 
Indiana 70 1.1 90 1.4 101 1.5 126 1.9 133 2.0 
Iowa 15 0.5 13 0.4 11 0.4 9 0.3 16 0.5 
Kansas 15 0.5 9 0.3 11 0.4 11 0.4 19 0.7 
Kentucky 151 3.5 180 4.1 214 4.9 164 3.7 162 3.7 
Louisiana 62 1.4 44 1.0 82 1.8 87 1.9 87 1.9 
Maine 8 0.6 9 0.7 11 0.8 12 0.9 9 0.7 
Maryland 62 1.1 52 0.9 43 0.7 40 0.7 40 0.7 
Massachusetts 67 1.0 75 1.1 71 1.1 30 0.4 25 0.4 
Michigan 91 0.9 81 0.8 53 0.5 50 0.5 56 0.6 
Minnesota 20 0.4 17 0.3 19 0.4 16 0.3 19 0.3 
Mississippi 57 1.9 78 2.6 55 1.8 48 1.6 50 1.7 
Missouri 60 1.0 48 0.8 61 1.0 31 0.5 35 0.6 
Montana 0 0.0 2 0.2 4 0.4 0 0.0 4 0.4 
Nebraska 12 0.7 10 0.5 9 0.5 8 0.4 3 0.2 
Nevada 29 1.1 28 1.0 29 1.0 21 0.7 25 0.9 
New 
Hampshire 
3 0.2 4 0.3 2 0.2 4 0.3 0 0.0 
New Jersey 73 0.8 70 0.8 65 0.7 77 0.9 85 0.9 
New Mexico 10 0.5 3 0.1 3 0.1 2 0.1 2 0.1 
New York 134 0.7 113 0.6 117 0.6 95 0.5 80 0.4 
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Table 3.1 (cont’d). Reported cases of acute hepatitis B, nationally and by state or jurisdiction 
― United States, 2011–2015 
State 
2011 2012 2013 2014 2015 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
North 
Carolina 
109 1.1 73 0.7 75 0.8 100 1.0 165 1.6 
North 
Dakota 
0 0.0 0 0.0 0 0.0 0 0.0 2 0.3 
Ohio 90 0.8 178 1.5 225 1.9 171 1.5 409 3.5 
Oklahoma 100 2.6 79 2.1 40 1.0 57 1.5 37 0.9 
Oregon 32 0.8 25 0.6 32 0.8 32 0.8 24 0.6 
Pennsylvania 84 0.7 63 0.5 43 0.3 68 0.5 61 0.5 
Rhode 
Island 
U U U U U U U U U U 
South 
Carolina 
39 0.8 37 0.8 58 1.2 37 0.8 30 0.6 
South 
Dakota 
2 0.2 2 0.2 5 0.6 3 0.4 2 0.2 
Tennessee 192 3.0 240 3.7 262 4.0 232 3.5 243 3.7 
Texas 204 0.8 170 0.7 142 0.5 122 0.5 159 0.6 
Utah 10 0.4 13 0.5 5 0.2 11 0.4 10 0.3 
Vermont 0 0.0 2 0.3 2 0.3 4 0.6 3 0.5 
Virginia 84 1.0 84 1.0 72 0.9 61 0.7 69 0.8 
Washington 35 0.5 34 0.5 33 0.5 44 0.6 34 0.5 
West 
Virginia 
113 6.1 141 7.6 195 10.5 186 10.1 272 14.7 
Wisconsin 17 0.3 22 0.4 9 0.2 11 0.2 5 0.1 
Wyoming 0 0.0 0 0.0 U U U U U U 
Total 2903 0.9 2895 0.9 3050 1.0 2791 0.9 3370 1.1 
Source: CDC, National Notifiable Diseases Surveillance System. 
*Rate per 100,000 population.
U=No data available for reporting.
 The number of acute hepatitis B cases reported in the United States decreased 0.3% from
2011 through 2012 (2,903 cases to 2,895 cases), increased 5.3% (to 3,050 cases) from 2012
through 2013, and decreased  8.5% (to 2,791 cases) from 2013 through 2014. Compared with
data for 2014, cases of acute hepatitis B increased 20.7% to 3,370 cases in 2015.
 The national rate of acute hepatitis B increased from 0.9 cases/100,000 population in 2014 to
1.1 cases/100,000 population in 2015.
 By state, 2015 rates of acute hepatitis B ranged from no cases reported in New Hampshire to
14.7 cases per 100,000 population in West Virginia.
o A 2.4-fold increase was observed in the number of acute hepatitis B cases reported in
Ohio, from 171 cases in 2014 to 409 cases in 2015.
o While Hawaii and Montana reported 2- and 4-fold increases from 2014 through 2015,
respectively, the number of reported cases remains <15, and rates remain lower than 
those at the national level. 
 	 Of the 48 states reporting cases of acute hepatitis B in 2015, a total of eight (i.e., California, 
Florida, Kentucky, North Carolina, Ohio, Tennessee, Texas, and West Virginia) accounted for 
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	  Of the 48 reporting states, 38 (79.2%) met the Healthy People 2020 goal 
(https://www.healthypeople.gov/) of reducing hepatitis B incidence to ≤1.5 cases/100,000 
population among adults, including: Alaska, Arizona, Arkansas, California, Colorado, 
Connecticut, Delaware, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Maryland, 
Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New 
Hampshire, New Jersey, New Mexico, New York, North Dakota, Oklahoma, Oregon, 
Pennsylvania, South Carolina, South Dakota, Texas, Utah, Vermont, Virginia, Washington, 
and Wisconsin. 
	  The incidence of acute hepatitis B was above the Healthy People 2020 goal for 10 states:  
Alabama, Florida, Indiana, Kentucky, Louisiana, Mississippi, North Carolina, Ohio, 
Tennessee, and West Virginia. 
	  Of the 10 states with rates above the Healthy People 2020 goal, four (Kentucky, Ohio, 






Table 3.2. Select clinical characteristics of acute hepatitis B cases* reported in the United States, 
2015. 
Clinical characteristic 
Availability of valid data† for 
clinical characteristic 
Cases with clinical 
characteristic§ 
No. % No. % 
Jaundice 2,526 75.0 1,891 74.9 
Hospitalized for hepatitis B 2,515 74.6 1,502 59.7 
Died from hepatitis B 2,311 68.6 20 0.9 
Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 3,370 hepatitis B cases were reported during 2015.
†Case reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with any other 
response were excluded. 
§Numbers and percentages represent only those case reports for which data regarding clinical characteristics were available;
numbers likely are underestimates.
 Of the 3,370 case reports of acute hepatitis B received in 2015, 75.0% included information
regarding whether the patient had jaundice, 74.6% included information regarding
hospitalization caused by hepatitis B, and 68.6% included information on death from hepatitis
B. (Note: more severe cases are likely to be ascertained and reported.)
 Jaundice was reported for 1,891 (74.9%) of the 2,526 acute hepatitis B case reports that
included information about jaundice.
 Hospitalization as the result of acute hepatitis B was reported for 1,502 (59.7%) of the 2,515
acute hepatitis B case reports that included information about hospitalization.
 Death from hepatitis B was reported for 20 (0.9%) of the 2,311 acute hepatitis B case reports
that included information about death
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 The number of reported acute hepatitis B cases declined 64.0%, from 8,036 in 2000 to 2,895 in 
2012; increased 5.3% (to 3,050 cases) from 2012 through 2013; and declined 8.5% (to 2,791 cases) 
from 2013 through 2014. Compared with 2014, cases increased 20.7% to 3,370 cases in 2015. 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2000 through 2015, the incidence of HBV cases reported in the United States was consistently
highest among the 30–39 year age group and lowest among the 0–19 year age group.
 From 2014 through 2015, the incidence of HBV cases reported in the United States increased for
persons in each of the age groups, except among those in the 0–19 year age group.
 In 2015, rates were highest for persons aged 30–39 years (2.6 cases/100,000 population); the lowest
rates were among children and adolescents aged <19 years (0.0 cases/100,000 population).
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Source: CDC, National Notifiable Diseases Surveillance System. 
 While the incidence of reported acute hepatitis B remained higher for males than for
females from 2000 through 2015, the gap narrowed from 2002 through 2015.
 In 2015, the rate for males was approximately 1.6 times higher than that for females
(1.3 cases and 0.8 cases per 100,000 population, respectively).
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Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2000 through 2015, the Asian/Pacific Islander population experienced the
steepest decline in the incidence rate of acute hepatitis B cases reported in the United
States, from 3.8 cases/100,000 population in 2000 to 0.4 cases/100,000 in 2015. The
non-Hispanic black and American Indian/Alaska Native populations also experienced
a notable decline in the incidence rate of acute hepatitis B.
 In 2015, the rate of acute hepatitis B was highest for non-Hispanic Whites (1.1 cases
per 100,000 population) and lowest among Hispanics and Asian/Pacific Islanders
(0.31 cases per 100,000 population and 0.35 cases per 100,000, respectively).
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Figure 3.5. Availability of information on risk exposures/behaviors associated with acute 










Source: CDC, National Notifiable Diseases Surveillance System. 
*Includes case reports indicating the presence of at least one of the following risks 6 weeks to 6 months prior to 
onset of acute, symptomatic hepatitis B: 1) using injection drugs; 2) having sexual contact with suspected/confirmed 
hepatitis B patient; 3) being a man who has sex with men; 4) having multiple sex partners concurrently; 5) having 
household contact with suspected/confirmed hepatitis B patient; 6) occupational exposure to blood; 7) being a 
hemodialysis patient; 8) having received a blood transfusion; 9) having sustained a percutaneous injury; and 10) 
having undergone surgery. 
 
 
 Of the 3,370 case reports of acute hepatitis B received by CDC during 2015, a total of 
1,163 (35%) did not include a response (i.e., a “yes” or “no” response to any of the 
questions about risk exposures and behaviors) to enable assessment of risk exposures 
or behaviors. 
 Of the 2,207 case reports that contained risk exposure/behavior information: 
o 1,151 (52.2%) indicated no risk exposure/behavior for acute hepatitis B. 
o 1,056 (47.8%)  indicated at least one risk exposure/behavior for acute hepatitis B 






























Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 3,370 case reports of acute hepatitis B were received in 2015. 
†More than one risk exposure/behavior may be indicated on each case report. 
§No risk data reported. 
¶A total of 2080 acute hepatitis B cases were reported among males in 2015. 
 
 
Figure 3.6a presents reported risk exposures/behaviors for acute hepatitis B during the 
incubation period, 2 weeks to 6 months prior to onset of symptoms. 
 
 Of the 1,657 case reports that included information about injection-drug use, 30.3% (n=502) 
indicated use of injection drugs. 
 Of the 1,025 case reports that included information about sexual contact, 3.3% (n=34) 
indicated sexual contact with a person with confirmed or suspected hepatitis B. 
 Of the 500 case reports from males that included information about sexual 
preference/practices, 11.8% (n=59) indicated sex with another man.  
 Of the 1,588 case reports that had information about number of sex partners, 26.4% (n=419) 
indicated having ≥2 sex partners. 
 Of the 1,025 case reports that included information about household contact, 1.7% (n=17) 
indicated household contact with a person with confirmed or suspected hepatitis B. 
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Source: CDC, National Notifiable Diseases Surveillance System.
*A total of 3,370 case reports of hepatitis B were received in 2015e.
†More than one risk exposure/behavior may be indicated on each case report
§No risk data reported..
Figure 3.6b presents reported risk exposures/behaviors for acute hepatitis B during the 
incubation period, 2 weeks to 6 months prior to onset of symptoms. 
 Of the 1,937 case reports that included information about occupational exposures, 0.6%
(n=12) indicated employment in a medical, dental, or other field involving contact with
human blood.
 Of the 1,287 case reports that included information about receipt of dialysis or kidney
transplant, 0.2% (n=2) indicated patient receipt of these procedures.
 Of the 1,700 case reports that included information about receipt of blood transfusion, 0.2%
(n=3) indicated patient receipt of a blood transfusion.
 Of the 1,659 case reports that included information about surgery, 10.6% (n=176) indicated
having surgery.
 Of the 1,517 case reports that included information about needle stick injury, 4.7% (n=71)




Chronic Hepatitis B 
In 2015, a total of 14,416 case reports of chronic hepatitis B were reported to CDC from 40 
states (Table 3.3). Despite increasing immune protection in young persons vaccinated in infancy, 
an analysis of chronic hepatitis B prevalence in racial and ethnic populations indicates that 
during 2011–2012, a total of 847,000 persons were living with HBV infection (which included 
~400,000 non-Hispanic Asians) in the noninstitutionalized U.S. population (8). 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
 
No symptoms are required. Persons with chronic HBV infection may have no evidence of liver 
disease or may have a spectrum of disease ranging from chronic liver disease to cirrhosis or liver 
cancer. 
Laboratory Criteria 
 IgM antibodies to IgM anti-HBc negative AND a positive result on one of the following 
tests: HBsAg, HBeAg, or nucleic acid test for hepatitis B virus DNA (including 
qualitative, quantitative and genotype testing), OR 
 HBsAg positive or nucleic acid test for HBV DNA positive (including qualitative, 
quantitative, and genotype testing) or HBeAg positive two times when tested least 6 
months apart. (Any combination of these tests performed 6 months apart is acceptable.)
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Table 3.3. Number of newly reported case* reports† of confirmed chronic hepatitis 
B submitted by states and jurisdictions, 2015 
State/Jurisdiction 
No. chronic 
hepatitis B case 






























New Hampshire N 
New Jersey 273 
New Mexico 41 
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Table 3.3 (cont’d). Number of newly reported case* reports† of confirmed chronic 
hepatitis B submitted by states and jurisdictions, 2015 
State/Jurisdiction 
No. chronic 
hepatitis B case 
reports submitted † 
New York 2,315 
North Carolina 507 





Rhode Island U 
South Carolina 156 











Source: CDC, National Notifiable Diseases Surveillance System. 
*For case definition, see https://wwwn.cdc.gov/nndss/conditions/hepatitis-b-chronic/case-definition/2012/
† Reports may not reflect unique cases.
§ Cases reported by California through NNDSS were all from San Francisco County. The number of cases in this
table and Table 3.4 differ because NNDSS and CDC’s Secure Access Management System (SAMS) have different
data close-out dates by which all annual data must be submitted.
N= Not Reportable, chronic hepatitis B infection is not reportable in the listed state.
U=No data available for reporting.
 In 2015, 40 states provided 14,416 case reports of chronic hepatitis B.
 Ten states (California, Florida, Georgia, Maryland, Missouri, New York, North
Carolina, Ohio, Pennsylvania, and Virginia) accounted for 72.9% of the chronic
hepatitis B cases reported through NNDSS in 2015.
 New York submitted the largest number of case reports (n= 2,315 or 16.1%) of
chronic hepatitis B in 2015.
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Table 3.4. Reported cases of chronic hepatitis B, by demographic characteristics and 
laboratory tests — Enhanced Viral Hepatitis Surveillance Sites, 2015 
Category 
FL* MA MI NYS† Phil SF WA Total 
No. No. No.  No. No.  No.  No.  No.  
 %§  % %  % % % % % 
Sex 
Female 
641 222 167 334 47 501 67 1979 
44.5% 47.0% 46.4% 43.1% 39.5% 47.0% 44.1% 45.1% 
Male 
798 250 193 440 71 566 83 2,401 
55.4% 53.0% 53.6% 56.8% 59.7% 53.0% 54.6% 54.7% 
Unknown /missing  
2 0 0 1 1 0 2 6 





0 8 6 1 1 0 0 16 
0.0% 1.7% 1.7% 0.1% 0.8% 0.0% 0.0% 0.4% 
Asian/Pacific 
Islander, NH 
81 159 90 265 45 562 22 1,224 
5.6% 33.7% 25.0% 34.2% 37.8% 52.7% 14.5% 27.9% 
Black,  NH 
187 87 46 92 23 13 12 460 
13.0% 18.4% 12.8% 11.9% 19.3% 1.2% 7.9% 10.5% 
White,   NH 
290 48 108 86 12 26 13 583 
20.1% 10.2% 30.0% 11.1% 10.1% 2.4% 8.6% 13.3% 
Hispanic 
90 15 5 40 5 20 4 179 
6.2% 3.2% 1.4% 5.2% 4.2% 1.9% 2.6% 4.1% 
Other,  NH 
47 28 22 33 4 10 5 149 
3.3% 5.9% 6.1% 4.3% 3.4% 0.9% 4.2% 3.4% 
Unknown /missing  
746 135 83 258 29 436 96 1783 
51.8% 28.6% 23.1% 33.3% 24.4% 40.9% 63.2% 40.7% 
Age group, years 
0-14 
9 6 8 4 1 7 3 38 
0.6% 1.3% 2.2% 0.5% 0.8% 0.7% 2.0% 0.9% 
15-24 
67 33 26 63 9 43 15 256 
4.6% 7.0% 7.2% 8.1% 7.6% 4.0% 9.9% 5.8% 
25-39 
428 209 116 292 41 339 52 1,477 
29.7% 44.3% 32.2% 37.7% 34.5% 31.8% 34.2% 33.7% 
40-54 
479 126 114 235 43 378 47 1,422 
33.2% 26.7% 31.7% 30.3% 36.1% 35.4% 30.9% 32.4% 
55+ 
458 98 96 181 25 303 35 1,196 
31.8% 20.8% 26.7% 23.4% 21.0% 28.4% 23.0% 27.3% 
Unknown /missing  
0 0 0 0 0 0 0 0 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
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Table 3.4 (cont’d). Reported cases of chronic hepatitis B, by demographic characteristics 
and laboratory tests — Enhanced Viral Hepatitis Surveillance Sites, 2015 
Category 
FL* MA MI NYS† Phil SF WA Total 
No. No. No. No. No. No. No. No. 
 %§  % %  % % % % % 
Place of birth 
United 
States 
0 25 85 5 51 14 0 180 




0 180 128 24 62 136 0 530 
0.0% 38.1% 35.6% 3.1% 52.1% 12.7% 0.0% 12.1% 
Unknown 
/missing 
1,441 267 147 746 6 917 152 3,676 
100.0% 56.6% 40.8% 96.3% 5.0% 85.9% 100.0% 83.8% 




1,301 398 270 690 97 943 90 3,789 
90.3% 84.3% 75.0% 89.0% 81.5% 88.4% 59.2% 86.4% 
[IgM anti-
HBc] - 
986 84 63 236 0 0 0 1,369 
68.4% 17.8% 17.5% 30.5% 0.0% 0.0% 0.0% 31.2% 
HBV "e" 
antigen + 
193 85 12 136 35 106 20 587 
13.4% 18.0% 3.3% 17.5% 29.4% 9.9% 13.2% 13.4% 
HBV NAT + 
652 382 13 338 99 941 24 2,449 
45.2% 80.9% 3.6% 43.6% 83.2% 88.2% 15.8% 55.8% 
Total no. 
cases 









7.1 6.9 3.6 6.9 7.6 123.4 2.1 7.6 
Source: CDC, Enhanced Viral Hepatitis Surveillance Sites. 
Abbreviations: FL, Florida, MA, Massachusetts; MI, Michigan; NYS, New York State; Phil, Philadelphia; SF, San Francisco; 
WA, Washington State; HBV: Hepatitis B Virus; IgM anti-HBc (Anti-Hepatitis B core IgM); NAT: HBV nucleic acid testing. 
Percentages may not sum to 100% due to rounding. 
* Florida DOH only reported cases from the following 10 counties: Alachua, Broward, Hillsborough, Miami-Dade,
Orange, Palm Beach, Pinellas, Polk, Sarasota, and Seminole.
†New York City was not included in the case count for New York State, therefore cases and population estimates from
New York excluded those who resided in New York City.
§The denominator used to calculate proportions was the total number of cases reported for each site.
¶NH: Non-Hispanic
**Cases can be reported with more than one laboratory test result.
††Population estimates for the United States: https://www.census.gov/quickfacts/table/PST045216/00
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 In 2015, a total of 4,386 chronic hepatitis B cases were reported by seven funded enhanced 
surveillance sites.  
 Among the 4,386 chronic hepatitis B cases,  
o 54.7% were among males and 
o 66.1% were among persons aged 25–54 years.  
 By site, the proportion of cases among males ranged from 53.0% in Massachusetts and San 
Francisco to 59.7% in Philadelphia; the proportion of Asian/Pacific Islanders with hepatitis 
B infection ranged from 5.6% in Florida to 52.7% in San Francisco. 
 Among the 710 cases for which place of birth was known, those born outside of the United 
States accounted for the greatest number of chronic hepatitis B cases (n=530, 74.6%). By 
site, among the cases for which place of birth was known, the proportion of reported chronic 
hepatitis B cases born outside of the United States ranged from 54.9% in Philadelphia to 
90.7% in San Francisco. In 2015, information on place of birth was not collected by Florida 
or Washington State. 
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Table 3.5. Number and rate* of hepatitis B-related deaths†, by demographic characteristics 
and year — United States, 2011–2015 
Demographic characteristic 
2011 2012 2013 2014 2015 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years)§ 
0–34 41 0.03 38 0.03 40 0.03 35 0.02 31 0.02 
35–44 143 0.35 123 0.30 146 0.36 126 0.31 120 0.30 
45–54 421 0.94 428 0.97 389 0.89 384 0.88 332 0.77 
55–64 645 1.69 639 1.66 704 1.79 684 1.71 611 1.49 
65–74 285 1.27 314 1.31 343 1.36 358 1.36 384 1.39 




832 0.32 818 0.31 868 0.33 853 0.32 809 0.30 
Black, NH 373 0.98 322 0.81 384 0.98 330 0.80 320 0.78 
Hispanic 161 0.48 139 0.39 149 0.39 155 0.38 134 0.32 
Asian/Pacific 
Islander 




9 0.38 18 0.74 14 0.55 11 0.43 16 0.58 
Sex 
Male 1,321 0.80 1,272 0.75 1,375 0.79 1,307 0.74 1,277 0.72 
Female 483 0.26 499 0.27 498 0.26 536 0.27 438 0.22 
Overall 1,804 0.52 1,771 0.50 1,873 0.52 1,843 0.50 1,715 0.45 
Source: CDC, National Vital Statistics System. 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000. 
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on 
the International Classification of Diseases, 10th Revision (ICD-10) codes B16, B17.0, B18.0, B18.1 (hepatitis B). 
§ One death in 2015 is not represented under the age group category due to missing data. 
¶ Seven deaths in 2011, five deaths in 2012, seven deaths in 2013, 16 deaths in 2014, and 16 deaths in 2015 are not 
represented under the race/ethnicity category due to missing data. 
 
 
 In 2015, the overall hepatitis B-related mortality rate was 0.45 deaths/100,000 population 
and was listed as an underlying cause of 1,715 deaths, representing a slight decline from the 
previous year. 
 From 2011 through 2014, the hepatitis B-related mortality rate remained relatively stable at 
0.50-0.52 deaths/100,000 population. In 2015, the rate slightly declined to 0.45 
deaths/100,000 population. 
 In 2015, Asians/Pacific Islanders had the highest hepatitis B-related mortality rate of 2.24 
deaths/100,000 population compared with other racial/ethnic populations. Persons aged 55–
64 years and 65–74 years had the highest age-specific mortality rates at 1.49 deaths/100,000 
population and 1.39 deaths/100,000 population, respectively. 
 In 2015, the hepatitis B-related mortality rate for males was more than three times the 
mortality rate for females (0.72 deaths/100,000 population vs. 0.22 deaths/100,000 
population). From 2011 through 2015, the hepatitis B-related mortality rate remained 
relatively stable for males and females
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Perinatal Hepatitis B 
Infants born to hepatitis B surface antigen (HBsAg)-positive women who become infected with 
hepatitis B at or near delivery are considered to have perinatal HBV infection; 90% of infants 
infected at birth go on to develop chronic hepatitis B. In 2015, a total of 37 cases of perinatal 
hepatitis B were reported to CDC from 18 states (Table 3.6).  
A 2009 modeling study estimates that 952 chronic hepatitis B cases occur each year among 
persons infected with HBV at birth, for a baseline annual rate of 3.84% (51).    
1995 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Perinatal hepatitis B in the newborn may range from asymptomatic to fulminant hepatitis. 
Laboratory Criteria 
 Hepatitis B surface antigen (HBsAg) positive
Case Classification 
Confirmed 
HBsAg positivity in any infant aged >1-24 months who was born in the United States or in U.S. 
territories to an HBsAg-positive mother. 
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Table 3.6. Number of newly reported case* reports† of perinatal hepatitis B§ submitted 
by states and jurisdictions, 2015 
State/Jurisdiction 
No. Perinatal 












New York 4 





West Virginia 2 
Wisconsin 2 
Total 37 
Source: CDC, National Notifiable Diseases Surveillance System. 
*For case-definition, see https://wwwn.cdc.gov/nndss/conditions/hepatitis-b-perinatal-virus-infection/case-
definition/1995/
†Reports may not reflect unique cases.
§ Perinatal hepatitis B is not a reportable disease in ALL jurisdictions.
 In 2015, a total of 18 states provided 37 case reports of perinatal hepatitis B.
 California had the highest number of newly reported case reports of perinatal hepatitis
B (n=11) in 2015.
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HEPATITIS C 
Acute Hepatitis C 
In 2015, a total of 2,436 cases of acute hepatitis C were reported to CDC from 41 states (Table 
4.1). The overall incidence rate for 2015 was 0.8 cases per 100,000 population, an increase from 
2011–2012. Actual acute cases are estimated to be 13.9 times the number of reported cases in 
any year. After adjusting for under-ascertainment and under-reporting, an estimated 33,900 
acute hepatitis C cases (95% CI=26,800–115,000) occurred in 2015. (Data for 2015 were 
unavailable for Alaska, Arizona, Connecticut, the District of Columbia, Hawaii, Iowa, 
Mississippi, New Hampshire, Rhode Island, and Wyoming.) 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
An acute illness with a discrete onset of any sign or symptom* consistent with acute viral 
hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal 
pain) and either a) jaundice or b) elevated serum alanine aminotransferase (ALT) levels >400 
IU/L. 
Laboratory Criteria 
Positive on one or more of the following three tests: 
 Antibodies to hepatitis C virus (anti-HCV) screening test with a signal-to-cutoff ratio
predictive of a true positive as determined for the particular assay as defined by CDC.
(URL for the signal to cut-off ratios: http://www.cdc.gov/hepatitis/HCV/LabTesting.htm)
OR
 Hepatitis C virus recombinant immunoblot assay (HCV RIBA)
OR
 Nucleic acid test (NAT) for HCV RNA (including qualitative, quantitative or genotype
testing)
AND meets the following two criteria (if additional testing is performed): 
 Absence of IgM antibody to hepatitis A virus (IgM anti-HAV)
AND
 Absence of IgM anti-HBc
*A documented negative HCV antibody laboratory test result followed within 6 months by a
positive test result (as described in the laboratory criteria for diagnosis) does not require an acute
clinical presentation to meet the surveillance case definition
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Table 4.1. Reported cases of acute hepatitis C, nationally and by state and jurisdiction ― 
United States, 2011-2015 
State 
2011 2012 2013 2014 2015 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
Alabama 23 0.5 24 0.5 30 0.6 35 0.7 70 1.4 
Alaska U U U U U U U U U U 
Arizona U U U U U U U U U U 
Arkansas 0 0.0 5 0.2 30 1.0 13 0.4 2 0.1 
California 48 0.1 63 0.2 72 0.2 73 0.2 59 0.2 
Colorado 28 0.5 42 0.8 21 0.4 33 0.6 40 0.7 
Connecticut 47 1.3 34 0.9 U U U U U U 
Delaware 3 0.3 U U U U U U 4 0.4 
District of 
Columbia 
U U U U U U U U U U 
Florida 64 0.3 107 0.6 134 0.7 93 0.5 126 0.6 
Georgia 53 0.5 82 0.8 48 0.5 57 0.6 84 0.8 
Hawaii U U U U U U U U U U 
Idaho 12 0.8 11 0.7 14 0.9 6 0.4 4 0.2 
Illinois 6 0.0 26 0.2 37 0.3 27 0.2 31 0.2 
Indiana 84 1.3 110 1.7 175 2.7 122 1.8 138 2.1 
Iowa 0 0.0 3 0.1 U U U U U U 
Kansas 8 0.3 16 0.6 17 0.6 28 1.0 22 0.8 
Kentucky 142 3.2 178 4.1 226 5.1 176 4.0 119 2.7 
Louisiana 7 0.2 11 0.2 19 0.4 22 0.5 24 0.5 
Maine 12 0.9 8 0.6 8 0.6 31 2.3 30 2.3 
Maryland 35 0.6 39 0.7 53 0.9 42 0.7 38 0.6 
Massachusetts 23 0.3 37 0.6 174 2.6 228 3.4 249 3.7 
Michigan 32 0.3 76 0.8 74 0.7 78 0.8 83 0.8 
Minnesota 17 0.3 32 0.6 47 0.9 40 0.7 37 0.7 
Mississippi U U U U U U U U U U 
Missouri 8 0.1 4 0.1 6 0.1 6 0.1 8 0.1 
Montana 9 0.9 9 0.9 16 1.6 13 1.3 15 1.5 
Nebraska 2 0.1 3 0.2 2 0.1 2 0.1 8 0.4 
Nevada 10 0.4 12 0.4 9 0.3 6 0.2 12 0.4 
New 
Hampshire 
U U U U U U U U U U 
New Jersey 53 0.6 71 0.8 106 1.2 113 1.3 130 1.5 
New Mexico 14 0.7 21 1.0 12 0.6 16 0.8 40 1.9 
New York 52 0.3 93 0.5 131 0.7 126 0.6 121 0.6 
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Table 4.1 (cont’d). Reported cases of acute hepatitis C, nationally and by state and 
jurisdiction ― United States, 2011-2015 
State 
2011 2012 2013 2014 2015 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
North 
Carolina 
60 0.6 63 0.6 79 0.8 111 1.1 144 1.4 
North 
Dakota 
0 0.0 0 0.0 4 0.6 0 0.0 0 0.0 
Ohio 6 0.1 7 0.1 116 1.0 105 0.9 122 1.1 
Oklahoma 53 1.4 80 2.1 40 1.0 45 1.2 35 0.9 
Oregon 20 0.5 37 0.9 14 0.4 15 0.4 13 0.3 
Pennsylvania 35 0.3 66 0.5 81 0.6 69 0.5 129 1.0 
Rhode 
Island 
U U U U U U U U U U 
South 
Carolina 
1 0.0 1 0.0 0 0.0 4 0.1 5 0.1 
South 
Dakota 
U U U U U U U U U U 
Tennessee 83 1.3 129 2.0 98 1.5 123 1.9 173 2.6 
Texas 37 0.1 44 0.2 28 0.1 47 0.2 48 0.2 
Utah 10 0.4 17 0.6 11 0.4 38 1.3 30 1.0 
Vermont 6 1.0 6 1.0 3 0.5 4 0.6 1 0.2 
Virginia 25 0.3 76 0.9 41 0.5 54 0.6 52 0.6 
Washington 41 0.6 54 0.8 63 0.9 82 1.2 63 0.9 
West 
Virginia 
46 2.5 55 3.0 58 3.1 62 3.4 63 3.4 
Wisconsin 15 0.3 26 0.5 40 0.7 49 0.9 64 1.1 
Wyoming 2 0.4 U U U U U U U U 
Total 1232 0.4 1778 0.6 2138 0.7 2194 0.7 2436 0.8 
Source: CDC, National Notifiable Diseases Surveillance System. 
*Rate per 100,000 population.
U=No data available for reporting.
 The number of acute hepatitis C cases reported in the United States increased 44.3%
from 2011 through 2012 (1,232 cases to 1,778 cases), increased 20.2% (to 2,138
cases) from 2012 through 2013, and increased 2.6% (to 2,194 cases) from 2013
through 2014. Compared with 2014, cases of acute HCV increased 11.0% (to 2,436
cases) in 2015.
 From 2014 through 2015, the national rate of acute cases of hepatitis C increased from
0.7 to 0.8 cases per 100,000 population.
 By state, in 2015 rates of acute hepatitis C ranged from no cases reported in North
Dakota to 3.7 cases per 100,000 population in Massachusetts.
 Of the 40 reporting states, 10 states (Florida, Indiana, Kentucky, Massachusetts, New
Jersey, New York, North Carolina, Ohio, Pennsylvania, and Tennessee) accounted for
59.6% of the acute hepatitis C cases reported in 2015.
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Map 4.1.  2015 State Acute Hepatitis C Incidence Compared to Healthy People 2020 National 
Goal*
Source: CDC, National Notifiable Diseases Surveillance System. 
 Of the 40 reporting states, the following 10 (25%) met the Healthy People 2020
(https://www.healthypeople.gov/) goal of reducing hepatitis C incidence to ≤0.25
cases/100,000 population: Arkansas, California, Idaho, Illinois, Missouri, North
Dakota, South Carolina, South Dakota, Texas, and Vermont.
 The incidence of acute hepatitis C was above the Healthy People 2020 goals for 31 of
the 40 reporting states:  Alabama, Colorado, Delaware, Florida, Georgia, Indiana,
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan,
Minnesota, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North
Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Tennessee, Utah, Virginia,
Washington, West Virginia, and Wisconsin.
 Of the 31 states with rates above the Healthy People 2020 goals, 26 states (Colorado,
Florida, Georgia, Indiana, Kansas, Kentucky, Maine, Maryland, Massachusetts,
Michigan, Minnesota, Montana, New Jersey, New Mexico, New York, North
Carolina, Ohio, Oklahoma,  Pennsylvania, Tennessee, Utah, Virginia, Washington,
West Virginia, and Wisconsin) had rates of acute hepatitis C that were more than
twice the national goal.
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Table 4.2. Select clinical characteristics of acute hepatitis C cases* reported in the United 
States, 2015 
Clinical characteristic 
Availability of valid data† for 
clinical characteristic 
Cases with clinical 
characteristic§ 
No. % No. % 
Jaundice 1,696 69.6 927 54.7 
Hospitalized for hepatitis C 1,552 63.7 822 53.0 
Died from hepatitis C 1,318 54.1 6 0.5 
Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,436 acute hepatitis C cases were reported during 2015.
†Case reports for which questions regarding clinical characteristics were answered with “yes” or “no.”
Reports with any other response were excluded.
§Numbers and percentages represent only those case reports for which data regarding clinical
characteristics were available; numbers likely are underestimates.
 Of the 2,436 acute hepatitis C case reports received during 2015, 69.6% (n=1,696)
included information about whether the case-patient had jaundice, 63.7% (n=1,552)
included information regarding hospitalization caused by hepatitis C, and 54.1%
(n=1,318) included information on death from hepatitis C. (Note: more severe cases
are likely to be ascertained and reported.)
 Jaundice was reported for 927 (54.7%) of the 1,696 acute hepatitis C case reports that
included information about jaundice.
 Hospitalization as the result of hepatitis C was reported for 822 (53.0%) of the 1,552
acute hepatitis C case reports that included information about hospitalization.
 Death from hepatitis C was reported for 6 (0.5%) of the 1,318 acute hepatitis C case-
reports that included information about death.
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Source: CDC, National Notifiable Diseases Surveillance System. 
 The number of reported acute hepatitis C cases declined 61.5%, from 3,197 in 2000 to
1,232 in 2011; increased 44.3% (to 1,778 cases) from 2011 through 2012; increased
20.3% (to 2,138 cases) from 2012 through 2013; and increased 2.6% (to 2,194 cases)
from 2013 through 2014. From 2014 through 2015, the number of acute HCV cases
increased 11.0% (to 2,436 cases).
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Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2000 through 2002, incidence rates for reported acute hepatitis C decreased among
all age groups except for persons aged 0–19 years; rates remained fairly constant among
all age groups from 2002 through 2010.
 From 2010 through 2015, the rate of acute hepatitis C increased among persons aged 20–
29, 30–39, and ≥60 years; the largest increases were among persons aged 20–29 years
(from 1.2 cases per 100,000 population in 2011 to 2.3 cases per 100,000 population in
2015) and persons aged 30–39 years (from 0.8 cases per 100,000 population in 2011 to
1.7 cases per 100,000 population in 2015).
 In 2015, among all age groups, persons aged 20–29 years had the highest rate (2.4 cases
per 100,000 population) and persons aged 0–19 and ≥60 years had the lowest rate (0.1
cases per 100,000 population) of acute hepatitis C.
 From 2014 through 2015, incidence rates for reported acute hepatitis C increased for all
age groups, except for persons aged ≥60 years. The largest increases were among persons
aged 20–29 years (from 2.2 cases per 100.000 population in 2014 to 2.4 cases per
100,000 population in 2015) and persons aged 50–59 years (from 0.4 cases per 100,000
population in 2011 to 0.6 cases per 100,000 population in 2015).
57  



































Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2011 through 2015, rates of acute hepatitis C increased among both males and females. 
 In 2015, rates among males and females were 0.9 and 0.7 cases per 100,000 population, 
respectively. 

















































Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2002 through 2010, the incidence rate of acute hepatitis C for American 
Indians/Alaska Natives remained high relative to other racial/ethnic groups. Incidence 
rates have since increased for all racial/ethnic populations. 
 From 2011 through 2015, the incidence rate of acute hepatitis C increased among all 
racial/ethnic groups except Asians/Pacific Islanders. 
 In 2015, the incidence rate per 100,000 population of acute hepatitis C was 1.8 for 
American Indians/Alaska Natives, 0.9 for non-Hispanic Whites, 0.3 for both 
Hispanics and non-Hispanic Blacks, and 0.1 for Asians/Pacific Islanders.  
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Figure 4.5.  Availability of information on risk exposures/behaviors associated with acute 










Source: CDC, National Notifiable Diseases Surveillance System. 
*Includes case reports indicating the presence of at least one of the following risks 2 weeks to 6 months prior to
onset of acute, symptomatic hepatitis C: 1) using injection drugs; 2) having sexual contact with
suspected/confirmed hepatitis C patient; 3) being a man who has sex with men; 4) having multiple sex partners
concurrently; 5) having household contact with suspected/confirmed hepatitis C patient; 6) having had occupational
exposure to blood; 7) being a hemodialysis patient; 8) having received a blood transfusion; 9) having sustained a
percutaneous injury; and 10) having undergone surgery.
 Of the 2,436 case reports of acute hepatitis C received by CDC during 2015, a total of
987 (40%) did not include a response (i.e., a “yes” or “no” response to any of the
questions about risk exposures and behaviors) to enable assessment of risk exposures
or behaviors.
 Of 1,449 case reports that contained risk exposure/behavior information:
o 500 (34.5%) indicated no risk exposure/behavior for acute hepatitis C and
o 949 (65.5%) indicated at least one risk exposure/behavior for acute hepatitis C
during the 2 weeks to 6 months prior to illness onset.
Surveillance for Viral Hepatitis — United States, 2015 
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Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,436 case reports of acute hepatitis C were received in 2015.
† More than one risk exposure/behavior may be indicated on each case report.
§No risk data reported.
¶A total of 1,334 acute hepatitis C cases were reported among males in 2015.
Figure 4.6a presents reported risk exposures/behaviors for acute hepatitis C during the 
incubation period, 2 weeks to 6 months prior to onset of symptoms. 
 Of the 1,182 case reports that contained information about injection-drug use, 64.2%
(n=759) indicated use of injection drugs.
 Of the 272 case reports from males that included information about sexual
preferences/practices, 8.5% (n=23) indicated sex with another man.
 Of the 43 case reports that had information about sexual contact, 14% (n=6) indicated
sexual contact with a person with confirmed or suspected hepatitis C.
 Of the 720 case reports that had information about number of sex partners, 29.6%
(n=213) indicated having ≥2 sex partners.
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Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,436 case reports of acute hepatitis C were received in 2015. 
†More than one risk exposure/behavior may be indicated on each case report. 
§No risk data reported. 
 
 
Figure 4.6b presents reported risk exposures/behaviors for acute hepatitis C during the 
incubation period, 2 weeks to 6 months prior to onset of symptoms. 
 
 Of the 1,071 case reports that included information about occupational exposures, 
0.75% (n=8) indicated employment in a medical, dental, or other field involving 
contact with human blood. 
 Of the 993 case reports that included information about receipt of dialysis or a 
kidney transplant, 0.6% (n=6) indicated patient receipt of dialysis or a kidney 
transplant. 
 Of the 907 case reports that included information about surgery, 10.4% (n=94) 
indicated having surgery. 
 Of the 884 case reports that included information about needle sticks, 8% (n=71) 
indicated having an accidental needle stick/puncture. 
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Hepatitis C, Past or Present 
In 2015, a total of 181,871 case reports of past or present hepatitis C were reported to CDC 
from 40 states (Table 4.3). Estimates based on the population sampled by the National Health 
and Nutrition Examination Survey (NHANES) indicate that approximately 2.7 million U.S. 
residents are living with chronic HCV infection (38).  
` 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
 
Most persons infected with HCV are asymptomatic; however, many have chronic liver disease, 
which can range from mild to severe. 
Laboratory Criteria 
 
One or more of the following three criteria (except in persons <18 months of age, for whom only 
the third criteria would satisfy the case classification): 
 Anti-HCV screening-test positive with a signal-to-cutoff ratio predictive of a true positive 
as determined for the particular assay as defined by CDC (URL for the signal-to-cutoff 
ratios: http://www.cdc.gov/hepatitis/HCV/LabTesting.htm) 
OR 
 HCV RIBA positive 
OR 
 NAT for HCV RNA positive (including qualitative, quantitative or genotype testing). 
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Table 4.3. Number of newly reported case* reports† of confirmed past or present 
hepatitis C submitted by states and jurisdictions, 2015 
State/Jurisdiction 
No. past/present 
hepatitis C case 






























New Hampshire N 
New Jersey 7,928 
New Mexico 3,680 
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Table 4.3 (cont’d). Number of newly reported case* reports† of confirmed past or 
present hepatitis C submitted by states and jurisdictions, 2015 
State/Jurisdiction 
No. past/present 
hepatitis C case 
reports† 
submitted  
New York  15,058 
North Carolina N 





Rhode Island U 
South Carolina 4,515 












Source: CDC, National Notifiable Diseases Surveillance System 
*For case definition, see https://wwwn.cdc.gov/nndss/conditions/hepatitis-c-chronic/case-definition/2012/ 
†Reports may not reflect unique cases. 
§ Cases reported by California through NNDSS were all from San Francisco County. Differences in the number of 
cases in this table and table 4.4 are because NNDSS and CDC’s Secure Access Management System (SAMS) have 
different data close-out dates by which all annual data must be submitted. 
N=Not Reportable, past/present hepatitis C is not reportable in the listed state. 
U= No data available for reporting. 
 
 
 In 2015, a total of 40 states notified CDC of 181,871 cases of past or present hepatitis C. 
 Eleven states (Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, 
New York, Ohio, Pennsylvania, Virginia) accounted for 67.6% of the past/present 
hepatitis C case reports submitted through NNDSS in 2015. 
 In 2015, the largest number of reports of past/present hepatitis C was received from 
Florida (n=22,793 or 12.6%). 
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Table 4.4. Reported cases of past or present hepatitis C, by demographic characteristics 
and laboratory tests — Enhanced Viral Hepatitis Surveillance Sites, 2015 
Category 
FL* MA MI NYS† Phil SF WA Total 
No.  No.  No.  No. No.  No.  No. No. 
%§ % % % % %  %  % 
Sex 
Female 
10,271 2,334 2,666 3,151 560 431 2,236 21,649 
40.2% 39.9% 37.9% 37.7% 33.5% 27.2% 37.6% 38.6% 
Male 
15,206 3,500 4,352 5,131 1,097 1,152 3,639 34,077 
59.5% 59.8% 61.9% 61.4% 65.7% 72.7% 61.1% 60.8% 
Unknown /missing 
98 21 14 71 14 2 80 303 





29 14 58 43 2 5 0 151 
0.1% 0.2% 0.8% 0.5% 0.1% 0.3% 0.0% 0.3% 
Asian/Pacific 
Islander,  NH 
54 97 44 97 13 57 39 404 
0.2% 1.7% 0.6% 1.2% 0.8% 3.6% 0.7% 0.7% 
Black, NH 
957 243 1,184 682 153 234 164 3,617 
3.7% 4.2% 16.8% 8.2% 9.2% 14.8% 2.8% 6.5% 
White, NH 
7,519 2,566 3,346 4,067 185 580 1,611 19,874 
29.4% 43.8% 47.6% 48.7% 11.1% 36.6% 27.1% 35.5% 
Hispanic 
1,135 330 112 541 89 116 135 2,458 
4.4% 5.6% 1.6% 6.5% 5.3% 7.3% 2.3% 4.4% 
Other,  NH 
271 210 86 132 12 0 42 753 
1.1% 3.6% 1.2% 1.6% 0.7% 0.0% 0.7% 1.3% 
Unknown /missing 
15,610 2,395 2,202 2,791 1,217 593 3,964 28,772 
61.0% 40.9% 31.3% 33.4% 72.8% 37.4% 66.6% 51.0% 
Age group, years 
0-14 
67 25 16 15 10 1 18 152 
0.3% 0.4% 0.2% 0.2% 0.6% 0.1% 0.3% 0.3% 
15-24 
2,343 794 537 1,064 58 35 427 5,258 
9.2% 13.6% 7.6% 12.7% 3.5% 2.2% 7.2% 9.4% 
25-39 
7,071 2,197 1,795 2,720 362 295 1,473 15,913 
27.6% 37.5% 25.5% 32.6% 21.7% 18.6% 24.7% 28.4% 
40-54 
6,314 1,285 1,454 1,787 466 452 1,590 13,348 
24.7% 21.9% 20.7% 21.4% 27.9% 28.5% 26.7% 23.7% 
55+ 
9,766 1,546 3,226 2,752 773 792 2,438 21,293 
38.2% 26.4% 45.9% 32.9% 46.3% 50.0% 40.9% 38.0% 
Unknown/missing 
14 8 4 15 2 10 9 62 
0.1% 0.1% 0.1% 0.2% 0.1% 0.6% 0.2% 0.1% 
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Table 4.4 (cont’d). Reported cases of past or present hepatitis C, by demographic 
characteristics and laboratory tests — Enhanced Viral Hepatitis Surveillance Sites, 2015 
Category 
FL* MA MI NYS† Phil SF WA Total 
No.  No.  No.  No. No.  No.  No. No. 
%§ % % % % %  %  % 
Hepatitis C laboratory testing** 
Anti-HCV+ 
15,975 4,613 4,861 5,715 987 977 3,862 36,990 
62.5% 78.8% 69.1% 68.4% 59.1% 61.6% 64.9% 66.0% 
HCV RNA+ 
15,226 4,505 2,318 5,862 1,639 1,179 2,656 33,385 
59.5% 76.9% 33.0% 70.2% 98.1% 74.4% 44.6% 59.6% 
Total no. cases   
 
25,575 5,855 7,032 8,353 1,671 1,585 5,955 56,026 
2015 Estimated 
population total†† 
20,271,272 6,794,422 9,922,576 11,245,386 1,567,442 864,816 7,170,351 57,836,265 
Rate per 100,000 
population 
126.2 86.2 70.9 74.3 106.6 183.3 83.1 96.9 
 
Source: CDC, Enhanced Viral Hepatitis Surveillance Sites. 
Abbreviations: FL, Florida; MA, Massachusetts; MI, Michigan; NYS, New York State; Phil, Philadelphia; SF, San Francisco; WA, 
Washington State; HCV: Hepatitis C virus; Anti-HCV: Hepatitis C Antibody: HCV RNA: Ribonucleic acid. 
* Florida DOH only reported cases from the following 10 counties:  
Alachua, Broward, Hillsborough, Miami-Dade, Orange, Palm Beach, Pinellas, Polk, Sarasota, and Seminole   
†Cases and population estimates from New York excluded those who resided in New York City because New York City was 
not included in the reported case counts. 
§ The denominator used to calculate proportions was the total number of cases reported for each site. 
¶NH: Non-Hispanic 
**Cases can be reported with more than one laboratory test result. 
††Population estimates for the United States: https://www.census.gov/quickfacts/table/PST045216/00  
 
 
 In 2015, a total of 56,029 cases of past or present hepatitis C were reported by the seven funded 
sites.  
 Among the 56,026 cases of past or present hepatitis C:  
o 60.8% were among males;  
o 61.6% were among persons aged 15–54 years;  
o 35.5% were among persons identifying as white, non-Hispanic;  
o 66.0% tested anti-HCV-positive; and  
o 65.6% tested HCV RNA-positive. 
 By site, the proportion of past or present hepatitis C cases among males ranged from 59.5% in 
Florida to 72.7% in San Francisco. Similarly, the proportion of past or present hepatitis cases 
among persons identifying as white, non-Hispanic ranged from 11.1% in Philadelphia to 48.7% in 
New York. 
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Table 4.5. Number and rate* of hepatitis C-related deaths†, by demographic characteristic 
and year — United States, 2011-2015 
Demographic characteristic 
2011 2012 2013 2014 2015 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years)§ 
0–34 128 0.09 158 0.11 121 0.08 162 0.11 196 0.13 
35–44 696 1.71 622 1.54 573 1.42 552 1.36 597 1.47 
45–54 5,073 11.34 4,749 10.73 4,344 9.93 4,118 9.48 3,676 8.51 
55–64 8,330 21.89 9,235 23.93 9,899 25.18 9,999 24.95 9,702 23.73 
65–74 2,136 9.50 2,515 10.49 3,004 11.91 3,390 12.84 4,023 14.60 




11,196 4.19 11,839 4.35 12,219 4.40 12,455 4.46 12,355 4.38 
Black, NH 3,167 7.89 3,232 7.81 3,520 8.35 3,540 8.12 3,606 8.14 
Hispanic 2,555 7.15 2,668 7.19 2,699 6.91 2,767 6.81 2,699 6.40 
Asian/Pacific 
Islander 




275 10.61 313 11.81 324 12.22 317 11.20 367 12.95 
Sex 
Male 12,651 7.11 13,300 7.31 13,745 7.40 13,998 7.39 14,095 7.31 
Female 5,070 2.70 5,350 2.77 5,623 2.85 5,661 2.81 5,534 2.71 
Overall 17,721 4.82 18,650 4.96 19,368 5.03 19,659 5.01 19,629 4.91 
Source: CDC, National Vital Statistics System. 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000. 
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the 
International Classification of Diseases, 10th Revision (ICD-10) codes B17.1, and B18.2 (hepatitis C). 
§One death in 2011, two deaths in 2012, two deaths in 2013, five deaths in 2014, and one death in 2015 are not 
represented under the age category due to missing age data. 
¶The race/ethnicity category was added starting in 2010 to incorporate bridged race categories. 73 deaths in 2011, 126 
deaths in 2012, 111 deaths in 2013, 142 deaths in 2014, and 157 in 2015 are not represented under the race/ethnicity 
category due to missing data. 
 
 As determined by death-certificate information, of the three types of viral hepatitis (hepatitis A, 
hepatitis B, and hepatitis C), hepatitis C was associated with the greatest number of deaths and 
the highest mortality rate in 2015, at 4.9 deaths/100,000 population. 
 The overall hepatitis C-related mortality rate increased from 4.8 deaths/100,000 population in 
2011 to 4.9 deaths/100,000 population in 2015. Compared with 2014, the rate of deaths in 2015 
declined slightly to 5.01/100,000. 
 In 2015, persons aged 55–64 years had the highest hepatitis C-related mortality rate (23.7 
deaths/100,000) compared with other age groups, accounting for 49.4% of hepatitis C-related 
deaths in 2015. 
 In 2015, American Indians/Alaska Natives had the highest hepatitis C-related mortality rate 
compared with other racial/ethnic populations, at 12.95 deaths/100,000 population. During 2011–
2015, the hepatitis C-related mortality rate among American Indians/Alaska Natives increased by 
13%. 
 In 2015, the hepatitis C-related mortality rate for males was approximately 2.7 times the rate for 
females.




National surveillance data for acute viral hepatitis provide essential information for identifying 
patterns and trends in viral hepatitis. These data can help public health entities 1) estimate the 
health burden of hepatitis A, hepatitis B, and hepatitis C at national, state, and local levels; 2) 
identify those populations for whom public health intervention is needed; and 3) evaluate 
intervention efforts. National rates for acute hepatitis A and B have been published since 1966, 
and national rates for acute hepatitis C (formerly non-A, non-B) have been published since 1992. 
Major changes in the epidemiology of these diseases have occurred since reporting of these 
infections was initiated, largely resulting from implementation of prevention strategies, 
including the introduction of effective vaccines against hepatitis A and hepatitis B. 
 
NNDSS, the core of viral hepatitis surveillance, was designed to enable states to notify CDC of 
cases of infectious diseases diagnosed with a single positive laboratory test. Cases of acute and 
chronic hepatitis B and C do not fit this pattern, as additional information beyond a single 
laboratory test is required to confirm a case (35). To better count and characterize cases of viral 
hepatitis and estimate the burden of disease, CDC supplements NNDSS data with data obtained 
from select funded sites, national surveys, and vital statistics. 
 
Data from NNDSS reveal that from 2014 through 2015, there was an increase of 12.2% in the 
number of reported cases of hepatitis A, a 20.7% increase in the number of reported cases of 
acute hepatitis B, and an 11% increase in the number of reported cases of hepatitis C.  
CDC was not alerted to any outbreaks of hepatitis A in 2015, but five states reported at least 20 
more cases in 2015 than were reported in 2014, representing an 18%–86% increase in reported 
cases and suggesting the occurrence of small outbreaks. Likewise, five states reported at least 50 
more cases (range: 50–238) in 2015 than in 2014, representing a 38%–139% increase in reported 
cases. Given the decreases in new infections during previous reporting periods, recent increases 
in hepatitis A and acute hepatitis B signal the continued need to increase hepatitis A and 
hepatitis B vaccination coverage among at-risk populations. The 11% increase in annual number 
of new HCV infections in 2015 reflects the epidemics of HCV transmission associated with 
growing numbers of young, non-urban (rural and Appalachian) white youth who have 
transitioned from oral prescription opioid abuse to injection of these opioids and heroin (16). In 
2015, after adjusting for under- ascertainment and under-reporting, the estimated numbers of 
cases of HAV, HBV, and HCV infections were 2,800, 21,900, and 33,900, respectively. 
 
Chronic hepatitis infection continues to affect millions of Americans (8, 38). In 2015, a total of 
14,416 reports of chronic hepatitis B and 181,871 reports of past or current hepatitis C were 
submitted to CDC through NNDSS. Mortality data from 2015 presented in this surveillance 
report show that certain socio-demographic groups are disproportionately dying with these 
infections, specifically 1) persons aged >55 years and American Indian/Alaska Natives (for 
hepatitis A); 2) persons aged >55 years of age (especially those 55–64 years of age) and 
Asians/Pacific Islanders (for hepatitis B); and 3) persons aged 55–64 years and American 
Indians/Alaska Native (for hepatitis C). Mortality rates in 2015 were highest among persons 
infected with HCV (4.91 deaths per 100,000 population), followed by HBV (0.45 deaths per 




CDC and state health departments rely on surveillance data to track the incidence of acute 
infection, guide development and evaluation of programs and policies for preventing infection, 
minimize the public health impact of viral hepatitis, and monitor progress towards achieving goals 
established for these programs and policies. Effective systems for conducting surveillance for 
chronic HBV and HCV infections are needed to ensure accurate reporting of all cases and to 
support and evaluate prevention activities. Additional investments in surveillance at the local, 
state, and national levels are essential to build strong prevention programs that interrupt 
transmission of viral hepatitis and improve the health of those who are currently infected.
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